Best Bank Stocks To Watch For 2018

On Tuesday, stocks fell in a slow session of low-volume trading that was short of any solid events that would shake out either buyers or sellers.

The Dow Jones Industrial Average fell 0.1%, the S&P 500 fell 0.3%, as did the Nasdaq, and the Russell 2000 led the indices lower by posting a loss of 0.7%.

It appears that many investors are waiting for a decision by the Federal Reserve on a further hike in interest rates before making commitments. The central bank of the U.S. is expected to raise short-term borrowing rates at its next meeting on March 14-15. The Fed may be influenced by the Labor Department’s release of the U.S employment figures for February, which will be announced on Friday.

Of the eleven sectors in the S&P 500, just one, Financials (up 0.5%), was a gainer. Telecommunications lost 0.8%, leading the list of ten losers.

At the end of the session, the Dow Jones Industrial Average fell 30 points to close at 20,925, the S&P 500 fell 7 to 2,368, the Nasdaq lost 15 points, closing at 5,834, and the Russell 2000 closed at 1,375 for a loss of 9 points. The NYSE’s primary exchange traded 793 million shares with total volume of 3.5 billion shares. The Nasdaq crossed 1.8 billion shares. On the Big Board, decliners outpaced advancers by 2.3-to-1, and on the Nasdaq, decliners led by 1.9-to-1. Blocks on the NYSE fell to 6,298 from 6,335 on Monday.

Best Bank Stocks To Watch For 2018: Golden Star Resources Ltd(GSS)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Golden Star (NYSEMKT: GSS) is a gold mining and exploration company, and operates gold mines in Ghana, West Africa. GSS is up 396% YTD after it announced in July that it had begun pre-commercial production of gold in an underground mine in Ghana. GSS is trading at $0.825 per share on Monday intraday.

Best Bank Stocks To Watch For 2018: Semtech Corporation(SMTC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Semtech Corporation (NASDAQ: SMTC) is projected to post its quarterly earnings at $0.27 per share on revenue of $128.38 million.

    Ollie’s Bargain Outlet Holdings Inc (NASDAQ: OLLI) is estimated to post its quarterly earnings at $0.17 per share on revenue of $190.44 million.

Best Bank Stocks To Watch For 2018: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:

  • [By Paul Ausick]

    Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

Best Bank Stocks To Watch For 2018: Marathon Petroleum Corporation(MPC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Marathon Petroleum Corporation (MPC) is an American petroleum refining, marketing, and transportation company headquartered in Findlay, Ohio, explains dividend reinvestment expert Vita Nelson, editor of DirectInvesting.

  • [By Stephen Mack]

    We’ve seen this happen before. In December, shares of Russian oil company Rosneft jumped 21% in two weeks when it was acquired by Glencore Plc. (LON: GLEN). And back in 2015, MarkWest Energy Partners LP (NYSE: MWE) enjoyed a similar jump when it was acquired by Marathon Petroleum Corp (NYSE: MPC).

Best Bank Stocks To Watch For 2018: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Best Bank Stocks To Watch For 2018: SPX Corporation(SPW)

Advisors’ Opinion:

  • [By Damon Churchwell]

    These companies manufacture processing products used by industries such as food and beverages, oil & gas, and wastewater treatment, among others. They serve a wide range of end markets that are mostly poised for increased earnings and are likely to spend on capital projects. While these positive trends persist, flow technology companies’ prospects ought to remain favorable. Let’shighlight several sector participants, starting with a top selection,SPX(NYSE: SPW),.